<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Lovastatin</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00227</strong>&#160; (APRD00370)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Lovastatin is a cholesterol-lowering agent that belongs to the class of medications called statins. It was the second agent of this class discovered. It was discovered by Alfred Alberts and his team at Merck in 1978 after screening only 18 compounds over 2 weeks. The agent, also known as mevinolin, was isolated from the fungi <i>Aspergillus terreus</i>. Research on this compound was suddenly shut down in 1980 and the drug was not approved until 1987. Interesting, Akira Endo at Sankyo Co. (Japan) patented lovastatin isolated from <i>Monascus ruber</i> four months before Merck. Lovastatin was found to be 2 times more potent than its predecessor, mevastatin, the first discovered statin. Like mevastatin, lovastatin is structurally similar to hydroxymethylglutarate (<span class="caps">HMG</span>), a substituent of <span class="caps">HMG</span>-Coenzyme A (<span class="caps">HMG</span>-CoA), a substrate of the cholesterol biosynthesis pathway via the mevalonic acid pathway. Lovastatin is a competitive inhibitor of <span class="caps">HMG</span>-CoA reductase with a binding affinity 20,000 times greater than <span class="caps">HMG</span>-CoA. Lovastatin differs structurally from mevastatin by a single methyl group at the 6&#8217; position. Lovastatin is a prodrug that is activated by <i>in vivo</i> hydrolysis of the lactone ring. It, along with mevastatin, has served as one of the lead compounds for the development of the synthetic compounds used today.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00227/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00227/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00227.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00227.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00227.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00227.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00227.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00227">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>6-alpha-methylcompactin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>6&#945;-methylcompactin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lovastatina</td><td>Spanish</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lovastatine</td><td>French</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Lovastatinum</td><td>Latin</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Altocor</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Altoprev</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Mevacor</td><td>Merck</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Advicor</td><td>niacin + lovastatin</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anticholesteremic-agents">Anticholesteremic Agents</a></li>
<li><a href="/mesh/hydroxymethylglutaryl-coa-reductase-inhibitors">Hydroxymethylglutaryl-CoA Reductase Inhibitors</a></li></ul></td></tr><tr><th>CAS number</th><td>75330-75-5</td></tr><tr><th>Weight</th><td>Average: 404.5396<br>Monoisotopic: 404.256274262</td></tr><tr><th>Chemical Formula</th><td>C<sub>24</sub>H<sub>36</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>PCZOHLXUXFIOCF-BXMDZJJMSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Lactones</td></tr><tr><th>Subclass</th><td>Delta Valerolactones</td></tr><tr><th>Direct parent</th><td>Delta Valerolactones</td></tr><tr><th>Alternative parents</th><td>Oxanes; Dicarboxylic Acids and Derivatives; Secondary Alcohols; Carboxylic Acid Esters; Enolates; Polyamines; Ethers</td></tr><tr><th>Substituents</th><td>oxane; dicarboxylic acid derivative; secondary alcohol; carboxylic acid ester; carboxylic acid derivative; ether; polyamine; enolate; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the delta valerolactones. These are cyclic organic compounds containing a 1-hydroxy-3,4,5,6-tetrahydro-1,2-thiazin-1- one moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For management as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia and mixed dyslipidemia. For primary prevention of coronary heart disease and to slow progression of coronary atherosclerosis in patients with coronary heart disease. </td></tr><tr><th>Pharmacodynamics</th><td>The primary cause of cardiovascular disease is atherosclerotic plaque formation. Sustained elevations of cholesterol in the blood increase the risk of cardiovascular disease. Lovastatin lowers hepatic cholesterol synthesis by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. At therapeutic doses, lovastatin decreases serum LDL cholesterol by 29-32%, increases high density lipoprotein (HDL) cholesterol by 4.6-7.3%, and decrease triglyceride levels by 2-12%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease. </td></tr><tr><th>Mechanism of action</th><td>Lovastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Lovastatin is a prodrug that is activated <i>in vivo</i> via hydrolysis of the lactone ring to form the &#946;-hydroxyacid. The hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind to HMG-CoA reductase with 20,000 times greater affinity than its natural substrate. The bicyclic portion of lovastatin binds to the coenzyme A portion of the active site. </td></tr><tr><th>Absorption</th><td>Studies suggest that </td></tr><tr><th>Volume of distribution</th><td><p>Lovastatin is able to cross the blood-brain-barrier and placenta.</p></td></tr><tr><th>Protein binding</th><td>Lovastatin and its &#946;-hydroxyacid metabolites are highly protein bound (&gt;95%).  </td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Lovastatin is hepatically metabolized in which the major active metabolites are the &#946;-hydroxyacid of lovastatin, the 6&#8217;-hydroxy derivative, and two additional metabolites. </p></td></tr><tr><th>Route of elimination</th><td>Lovastatin undergoes extensive first-pass extraction in the liver, its primary site of action, with subsequent excretion of drug equivalents in the bile. 83% of the orally administered dose is excreted in bile and 10% is excreted in urine. </td></tr><tr><th>Half life</th><td>5.3 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>LD<sub>50</sub>&gt;1000 mg/kg (orally in mice)</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Lovastatin Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00099?highlight%5Bcompounds%5D%5B%5D=DB00227&amp;highlight%5Bproteins%5D%5B%5D=DB00227">SMP00099</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9452</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9287</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5484</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7861</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.7046</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8388</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8299</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8333</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6868</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9291</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.923</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8682</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.8475
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9519
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8819
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.0554 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.7272
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.7484
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Andrx labs llc</li>
<li>Actavis elizabeth llc</li>
<li>Apotex inc</li>
<li>Carlsbad technology inc</li>
<li>Lupin ltd</li>
<li>Mutual pharmaceutical co inc</li>
<li>Mylan pharmaceuticals inc</li>
<li>Sandoz inc</li>
<li>Teva pharmaceuticals usa inc</li>
<li>Merck research laboratories div merck co inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actavis.com">Actavis Group</a></li>
<li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li><a href="http://www.apotex.com">Apotex Inc.</a></li>
<li>Apotheca Inc.</li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.carlsbadtech.com">Carlsbad Technology Inc.</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>DHHS Program Support Center Supply Service Center</li>
<li><a href="http://www.drxdispensing.com">Dispensing Solutions</a></li>
<li><a href="http://www.dhscorp.com">Diversified Healthcare Services Inc.</a></li>
<li>Eon Labs</li>
<li>Heartland Repack Services LLC</li>
<li>International Laboratories Inc.</li>
<li>Ivax Pharmaceuticals</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.lupinpharmaceuticals.com">Lupin Pharmaceuticals Inc.</a></li>
<li><a href="http://www.majorpharmaceuticals.com">Major Pharmaceuticals</a></li>
<li><a href="http://www.mckesson.com">Mckesson Corp.</a></li>
<li><a href="http://www.medvantx.com">Medvantx Inc.</a></li>
<li><a href="http://www.merck.com">Merck &amp; Co.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Mutual Pharmaceutical Co.</li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.palmettopharm.com">Palmetto Pharmaceuticals Inc.</a></li>
<li>PCA LLC</li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.pharmedixrx.com">Pharmedix</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.preferredpharmaceuticals.com">Preferred Pharmaceuticals Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandhillspackaging.com">Sandhills Packaging Inc.</a></li>
<li>Sciele Pharma Inc.</li>
<li><a href="http://www.shionogi-inc.com">Shionogi Pharma Inc.</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li>
<li><a href="http://www.udllabs.com">UDL Laboratories</a></li>
<li>Va Cmop Dallas</li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.watson.com">Watson Pharmaceuticals</a></li>
<li><a href="http://www.ysp.com.cn">Yung Shin Pharmaceutical Industry Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>10 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>20 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>40 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Altoprev 60 mg 24 Hour tablet</td><td>7.99USD</td><td>tablet</td></tr><tr><td>Altoprev 60 mg tablet</td><td>7.74USD</td><td>tablet</td></tr><tr><td>Altoprev 20 mg 24 Hour tablet</td><td>6.88USD</td><td>tablet</td></tr><tr><td>Altoprev 20 mg tablet</td><td>6.61USD</td><td>tablet</td></tr><tr><td>Mevacor 40 mg tablet</td><td>4.57USD</td><td>tablet</td></tr><tr><td>Altoprev 40 mg tablet</td><td>4.41USD</td><td>tablet</td></tr><tr><td>Lovastatin 40 mg tablet</td><td>4.36USD</td><td>tablet</td></tr><tr><td>Altoprev 10 mg 24 Hour tablet</td><td>3.07USD</td><td>tablet</td></tr><tr><td>Mevacor 20 mg tablet</td><td>2.53USD</td><td>tablet</td></tr><tr><td>Lovastatin 20 mg tablet</td><td>2.42USD</td><td>tablet</td></tr><tr><td>Altocor 20 mg 24 Hour tablet</td><td>2.36USD</td><td>tablet</td></tr><tr><td>Apo-Lovastatin 40 mg Tablet</td><td>2.11USD</td><td>tablet</td></tr><tr><td>Co Lovastatin 40 mg Tablet</td><td>2.11USD</td><td>tablet</td></tr><tr><td>Mylan-Lovastatin 40 mg Tablet</td><td>2.11USD</td><td>tablet</td></tr><tr><td>Novo-Lovastatin 40 mg Tablet</td><td>2.11USD</td><td>tablet</td></tr><tr><td>Pms-Lovastatin 40 mg Tablet</td><td>2.11USD</td><td>tablet</td></tr><tr><td>Ran-Lovastatin 40 mg Tablet</td><td>2.11USD</td><td>tablet</td></tr><tr><td>Ratio-Lovastatin 40 mg Tablet</td><td>2.11USD</td><td>tablet</td></tr><tr><td>Sandoz Lovastatin 40 mg Tablet</td><td>2.11USD</td><td>tablet</td></tr><tr><td>Mevacor 10 mg tablet</td><td>1.65USD</td><td>tablet</td></tr><tr><td>Lovastatin 10 mg tablet</td><td>1.37USD</td><td>tablet</td></tr><tr><td>Apo-Lovastatin 20 mg Tablet</td><td>1.14USD</td><td>tablet</td></tr><tr><td>Co Lovastatin 20 mg Tablet</td><td>1.14USD</td><td>tablet</td></tr><tr><td>Mylan-Lovastatin 20 mg Tablet</td><td>1.14USD</td><td>tablet</td></tr><tr><td>Novo-Lovastatin 20 mg Tablet</td><td>1.14USD</td><td>tablet</td></tr><tr><td>Pms-Lovastatin 20 mg Tablet</td><td>1.14USD</td><td>tablet</td></tr><tr><td>Ran-Lovastatin 20 mg Tablet</td><td>1.14USD</td><td>tablet</td></tr><tr><td>Ratio-Lovastatin 20 mg Tablet</td><td>1.14USD</td><td>tablet</td></tr><tr><td>Sandoz Lovastatin 20 mg Tablet</td><td>1.14USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6080778</td><td>1998-03-23</td><td>2018-03-23</td></tr><tr><td>United States</td><td>5916595</td><td>1997-12-12</td><td>2017-12-12</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>174.5 &#176;C</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>0.0004 mg/mL</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>4.26</td><td>HANSCH,C ET AL. (1995)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>2.43e-02 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.11</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.9</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.2</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>14.91</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-2.8</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>72.83</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>113.18</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>46.11</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Donald F. Gerson, Xinfa Xiao, &#8220;Process for the production of lovastatin using Coniothyrium fuckelii.&#8221; U.S. Patent US5409820, issued January, 1984.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=5409820&amp;tbm=pts" target="_blank">US5409820 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Bobek P, Ozdin L, Galbavy S: Dose- and time-dependent hypocholesterolemic effect of oyster mushroom (Pleurotus ostreatus) in rats. Nutrition. 1998 Mar;14(3):282-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9583372">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00359" target="_blank">D00359 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07074" target="_blank">C07074 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=53232" target="_blank">53232 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508223" target="_blank">46508223 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.48085.html" target="_blank">48085 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=40303" target="_blank">40303 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL503" target="_blank">CHEMBL503 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000551" target="_blank">DAP000551 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA450272" target="_blank">PA450272 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=2739" target="_blank">2739 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2739" target="_blank">2739 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>HET</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/msd-srv/chempdb/cgi-bin/cgi.pl?FUNCTION=getByCode&amp;CODE=803" target="_blank">803 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2243127" target="_blank">2243127 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic3/altocor.htm" target="_blank">http://www.rxlist.com/cgi/generic3/altocor.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/lovastatin.html" target="_blank">http://www.drugs.com/cdi/lovastatin.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Lovastatin" target="_blank">Lovastatin <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C10AA02<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C10#C10">C10 &#8212; LIPID MODIFYING AGENTS</a></li><li><a href="/atc/C10A#C10A">C10A &#8212; LIPID MODIFYING AGENTS, PLAIN</a></li><li><a href="/atc/C10AA#C10AA">C10AA &#8212; HMG CoA reductase inhibitors</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:06.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00227.pdf?1265922804">show</a>(126 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00227.pdf?1373604375">show</a>(99.6 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Lovastatin may increase the anticoagulant effect of acenocoumarol. Monitor for changes in the therapeutic and adverse effects of acenocoumarol if lovastatin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00701">Amprenavir</a></td><td>Amprenavir may increase the serum concentration of the lovastatin. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Lovastatin may increase the anticoagulant effect of anisindione. Monitor for changes in the therapeutic and adverse effects of anisindione if lovastatin if initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01072">Atazanavir</a></td><td>Atazanavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00207">Azithromycin</a></td><td>The macrolide antibiotic, azithromycin, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if azithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01393">Bezafibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00559">Bosentan</a></td><td>Bosentan may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if bosentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Carbamazepine, a p-glycoprotein inducer and strong CYP3A4 inducer, may decrease the effect of lovastatin by increasing its efflux and metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if carbamazepine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the toxicity of the statin, lovastatin.</td></tr><tr><td><a href="/drugs/DB01394">Colchicine</a></td><td>Increased risk of rhabdomyolysis with this combination</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Possible myopathy and rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01406">Danazol</a></td><td>Risk of severe myopathy/rhabdomyolysis with this combination</td></tr><tr><td><a href="/drugs/DB01264">Darunavir</a></td><td>Darunavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated. 
</td></tr><tr><td><a href="/drugs/DB00705">Delavirdine</a></td><td>Delavirdine, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if delavirdine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Lovastatin may increase the anticoagulant effect dicumarol. Monitor for changes in the therapeutic and adverse effects of dicumarol if lovastatin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00343">Diltiazem</a></td><td>Diltiazem may increase the serum concentration of lovastatin. Lovastatin may increase the serum concentration of diltiazem. Monitor for changes in the therapeutic and adverse effects of both agents if concomitant therapy is initiated, discontinued or if doses are changed.</td></tr><tr><td><a href="/drugs/DB00625">Efavirenz</a></td><td>Efavirenz may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if efavirenz is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the toxicity of the statin, lovastatin.</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Lovastatin, when administered concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to monitor continued efficacy of lovastatin therapy. </td></tr><tr><td><a href="/drugs/DB01039">Fenofibrate</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01319">Fosamprenavir</a></td><td>Fosamprenavir, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01241">Gemfibrozil</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB00619">Imatinib</a></td><td>Imatinib, a strong CYP3A4 inhibitor, may increase the effect and toxicity of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if imatinib is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00224">Indinavir</a></td><td>Indinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>The macrolide, josamycin, may increase the toxicity of the statin, lovastatin.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Increased risk of myopathy/rhabdomyolysis</td></tr><tr><td><a href="/drugs/DB08827">Lomitapide</a></td><td>Lovastatin plasma concentrations may increase by lomitapide.</td></tr><tr><td><a href="/drugs/DB01149">Nefazodone</a></td><td>Nefazodone, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if nefazodone is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00220">Nelfinavir</a></td><td>Nelfinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00238">Nevirapine</a></td><td>The strong CYP3A4 inducer, nevirapine, may decrase the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if nevirapine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00627">Niacin</a></td><td>Risk of severe myopathy/rhabdomyolysis with this combination</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00615">Rifabutin</a></td><td>Rifabutin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifabutin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB01045">Rifampicin</a></td><td>Rifampin may decrease the effect of lovastatin by increasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of lovastatin if rifampin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01232">Saquinavir</a></td><td>Saquinavir may increase the effect and toxicity of lovastatin. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB05521">Telaprevir</a></td><td>Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may increase the adverse effects of lovastatin by decreasing its metabolism. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08816">Ticagrelor</a></td><td>Patients receiving more than 40 mg per day of lovastatin may be at increased risk of statin-related adverse effects. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Lovastatin. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00661">Verapamil</a></td><td>Verapamil, a moderate CYP3A4 inhibitor, may increase the serum concentration of Lovastatin by decreasing its metabolism. Avoid concurrent use if possible or reduce lovastatin dose during concomitant therapy. Monitor for changes in the therapeutic/adverse effects of Lovastatin if Verapamil is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of lovastatin by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Lovastatin may increase the anticoagulant effect warfarin.  Monitor for changes in the therapeutic and adverse effects of warfarin if lovastatin is initiated, discontinued or dose changed .</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Avoid drastic changes in dietary habit.</li>
<li>Avoid taking with grapefruit juice.</li>
<li>Take with food, 50% increase in bioavailability when taken with food.</li></ul></td></tr></tbody></table>